• Publications
  • Influence
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
The addition of omalizumab to standard asthma therapy reduces asthma exacerbations and decreases inhaled corticosteroid and rescue medication use.
Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma
Patients who received dupilumab had significantly lower rates of severe asthma exacerbation than those who received placebo, as well as better lung function and asthma control.
Lebrikizumab treatment in adults with asthma.
Lebrikizumab treatment was associated with improved lung function and patients with high pretreatment levels of serum periostin had greater improvement in lung function with lebrikIZumab than did patients with low periOSTin levels.
Tezepelumab in Adults with Uncontrolled Asthma.
This research presents a meta-analysis of six immune checkpoint checkpoints in rats that shows clear patterns of action towards certain immune checkpoints that are hallmarks of “clinically checkpoints” in animals.
Review of alleged reaction to monosodium glutamate and outcome of a multicenter double-blind placebo-controlled study.
Large doses of MSG given without food may elicit more symptoms than a placebo in individuals who believe that they react adversely to MSG, but the frequency of the responses was low and the responses reported were inconsistent and were not reproducible.
Conjunctivitis in dupilumab clinical trials
Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate‐to‐severe atopic dermatitis (AD) uncontrolled
Role of Interleukin-13 in Asthma
  • J. Corren
  • Medicine, Biology
    Current Allergy and Asthma Reports
  • 12 September 2013
Data indicate that IL-13 antagonists may fulfill an important unmet need in patients with poorly controlled asthma and biologic evidence of persistent IL- 13 activity is demonstrated.
Intranasal corticosteroids for allergic rhinitis: how do different agents compare?
  • J. Corren
  • Medicine
    The Journal of allergy and clinical immunology
  • 1 October 1999
Efficacy of soluble IL-4 receptor for the treatment of adults with asthma.
These promising data suggest that IL-4R is safe and effective in the treatment of moderate persistent asthma.